5-Fluorouracil 0.5% and salicylic acid 10.0% (Actikerall)
In Canada, 74,100 new cases of non-melanoma skin cancers (NMSCs) and 270 deaths due to these cancers were predicted for 2011.2 AK typically manifests as 2 mm to 6 mm scaly macules, papules, or plaques that are skin to reddish-brown in colour, and may be flat or thickened (hyperkeratotic).4,5 Patient...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, 2017
|
| Series: | Common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | In Canada, 74,100 new cases of non-melanoma skin cancers (NMSCs) and 270 deaths due to these cancers were predicted for 2011.2 AK typically manifests as 2 mm to 6 mm scaly macules, papules, or plaques that are skin to reddish-brown in colour, and may be flat or thickened (hyperkeratotic).4,5 Patients with AK are usually referred to dermatologists and diagnosis is frequently made on clinical appearance alone.1 A skin biopsy may be required when there is clinical doubt or suspicion of invasive malignancy.1,5 Detectable AK may be associated with a field change where the surrounding skin is also altered and subclinical lesions may be present.2 Patient input to the CADTH Common Drug Review (CDR) suggests that cosmetic issues are a major concern for patients, and this can have a negative impact on self-confidence. The submitted product is a combination of two topical therapies, 5-fluorouracil 0.5% (5-FU) and salicylic acid 10% (SA). According to the British Association of Dermatologists, 15% to 25% of actinic keratosis (AK) lesions spontaneously resolve during a one-year period.1 However, AK lesions may develop into invasive squamous cell carcinoma (SCC) if left untreated.2 The rate of progression from AK to SCC is unknown. Mathematical models derived from a study predicted that for an individual with an average of 7.7 AKs, the probability of developing an SCC at the same or nearby site within a 10-year period is approximately 10.3 The risk of malignant transformation is higher in patients who are immunocompromised. 5-FU is an antimetabolite that is already approved as monotherapy for treatment of AK, although at a concentration of 5%. SA is a keratolytic, and the theory behind its use is to improve penetration of the combination in hyperkeratotic AK. The 5-FU/SA combination under review is administered once daily to affected lesions, until lesions have cleared or for a maximum of 12 weeks. It is indicated for the management of grade I/II hyperkeratotic AK. The objective of this report was to perform a systematic review of the beneficial and harmful effects of 5-FU (0.5%) combined with SA 10% applied topically once daily for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (grade I/II) of the face, forehead, and balding scalp in immunocompetent adult patients |
|---|---|
| Physical Description: | 1 online resource illustrations |